Ceftriaxone 2g Powder for Solution for Injection or Infusion
Ceftriaxone sodium equivalent to 2g ceftriaxone per vial.
Each gram of ceftriaxone sodium contains approximately 3.6 mmol sodium.
2 g Powder for Solution for injection or infusion
Powder for solution for injection or infusion.
• Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth)
• Bacterial Meningitis
• Community acquired pneumonia
• Hospital acquired pneumonia
• Acute otitis media
• Intra-abdominal infections
• Complicated urinary tract infections (including pyelonephritis)
• Infections of bones and joints
• Complicated skin and soft tissue infections
• Gonorrhoea
• Syphilis
• Bacterial endocarditis
Ceftriaxone may be used:
For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults
For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.
For pre-operative prophylaxis of surgical site infections
In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection
In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above
Ceftriaxone should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4).
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
Posology
The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.
The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered.
Adults and children over 12 years of age (≥ 50 kg)
|
Ceftriaxone Dosage*
|
Treatment frequency**
|
Indications
|
|
1 - 2 g
|
Once daily
|
Community acquired pneumonia
|
|
Acute exacerbations of chronic obstructive pulmonary disease
|
|
Intra-abdominal infections
|
|
Complicated urinary tract infections (including pyelonephritis)
|
|
2 g
|
Once daily
|
Hospital acquired pneumonia
|
|
Complicated skin and soft tissue infections
|
|
Infections of bones and joints
|
|
2 – 4 g
|
Once daily
|
Management of neutropenic patients with fever that is suspected to be due to a bact |
